One John Marshall Drive
Robert C. Byrd Biotechnology Science Center, Suite 314
Huntington, WV 25755
Engineering Bacteria for FDA-Approval
Pseudomonas aeruginosa is an opportunistic human pathogen. It also produces products of potential concern to the FDA that could contaminate alginate and engender costly extraction techniques to eliminate these products. Therefore, Progenesis has engineered a strain of Pseudomonas aeruginosa lacking the genes that encode these products. Also, Progenesis has identified a gene crucial for P. aeruginosa pathogenesis. Eliminating this gene yields a strain that lacks virulence in mice.
As a complementary approach, Progenesis is engineering the Pseudomonas species fluorescens and putida, since they are not classified as human pathogens. Based on DNA sequence analysis, these species have different mechanism for regulating alginate biosynthesis. Progenesis is pursuing several engineering approaches to unlocking high and stable alginate production in these species, as well as removing any genes that might encode products of concern to the FDA.